Table 1.
Patient and tumor characteristics. RNA was isolated from AI-treated ER+ tumors from patients who had not recurred (“AI-sensitive,” “controls,” n = 37) or who recurred within 5 years after diagnosis (“resistant,” “cases,” n = 17)
| AI sensitive (controls; N = 37) | AI resistant (cases; N = 17) | Fisher’s exact test of t test p value | |
|---|---|---|---|
| Age at diagnosis (years) mean (SD) [min, max] | 62 (10) [44,81] | 60 (12) [35,78] | 0.4533 |
| Date diagnosis | 2002–2005 | 2002–2006 | NA |
| Disease-free follow-up (years) median [min, max] | 8.6 [5.0, 11.9] | 3.3 [1.9, 4.6] | NA |
| Histology | |||
| IDC | 24 (65 %) | 13 (76 %) | 0.7352 |
| ILC, mixed, or other | 5 (14 %) | 1 (6 %) | |
| Tumor size | 8 (22 %) | 3 (18 %) | |
| Stage | |||
| 1 | 17 (46 %) | 6 (35 %) | 0.5414 |
| 2 | 16 (43 %) | 8 (47 %) | |
| 3 | 4 (11 %) | 2 (12 %) | |
| 4 | 0 (0 %) | 1 (6 %) | |
| PR+ | 31 (84 %) | 13 (76 %) | 0.7075 |
| Adjuvant chemotherapy | 18 (49 %) | 7 (41 %) | 0.7703 |
| Radiation therapy | 21 (57 %) | 15 (88 %) | 0.0303 |
| Grade | |||
| 1 | 13 (36 %) | 0 (0 %) | 0.0024 |
| 2 | 17 (47 %) | 8 (50 %) | |
| 3 | 6 (17 %) | 8 (50 %) | |
Tumors from patients treated with neoadjuvant therapy were excluded